Prescription savings platform GoodRx is collaborating with pharma giant Novo Nordisk to make Ozempic and Wegovy pens ...

We live in a world where $1 billion of prescription medications are left at the pharmacy counter each year, often because ...

Hims & Hers investors hit with more bad news as Novo Nordisk partners with GoodRx to offer discounted access to competing products. ETFs with high concentration in HIMS may face risks and losses.

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

“The number of people with no commercial insurance coverage for Zepbound increased by over 180% in 2025, leaving over 97 million people with no coverage,” a new study from GoodRx found ... to a lesser ...

Moderately bullish activity in Hims and Hers Health (HIMS), with shares down $1.36 near $43.21. Options volume relatively light with 86k contracts ...